Limits...
Mortality in levodopa-treated Parkinson's disease.

Morgan JC, Currie LJ, Harrison MB, Bennett JP, Trugman JM, Wooten GF - Parkinsons Dis (2014)

Bottom Line: Our findings confirm that PD is associated with increased mortality in both men and women.Unlike the majority of other mortality studies, we found that women have a greater reduction in lifespan compared to men.We also found that patients with early onset PD (onset at the age of 50 or before) have reduced survival relative to PD patients with later ages of onset.

View Article: PubMed Central - PubMed

Affiliation: Movement Disorders Program, Department of Neurology, Medical College of Georgia, Georgia Regents University, 1429 Harper Street HF-1154, Augusta, GA 30912, USA.

ABSTRACT
Parkinson's disease (PD) is associated with increased mortality despite many advances in treatment. Following the introduction of levodopa in the late 1960's, many studies reported improved or normalized mortality rates in PD. Despite the remarkable symptomatic benefits provided by levodopa, multiple recent studies have demonstrated that PD patients continue to die at a rate in excess of their peers. We undertook this retrospective study of 211 deceased PD patients to determine the factors associated with mortality in levodopa-treated PD. Our findings confirm that PD is associated with increased mortality in both men and women. Unlike the majority of other mortality studies, we found that women have a greater reduction in lifespan compared to men. We also found that patients with early onset PD (onset at the age of 50 or before) have reduced survival relative to PD patients with later ages of onset. A final important finding is that survival is equal in PD patients treated with levodopa early (within 2 years or less of PD onset) versus later.

No MeSH data available.


Related in: MedlinePlus

Survival analysis of PD men and PD women versus control men and control women from the U.S. population. PD men and PD women have no difference in survival, while both PD men and PD women have reduced survival relative to control men and control women, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3927757&req=5

fig2: Survival analysis of PD men and PD women versus control men and control women from the U.S. population. PD men and PD women have no difference in survival, while both PD men and PD women have reduced survival relative to control men and control women, respectively.

Mentions: A Kaplan-Meier survival analysis illustrated in Figure 1 reveals that survival is reduced on average by 7 years in the entire sample of PD patients compared to an age-, gender-, and race-matched control group from the U.S. population. Men with PD had a mean reduction in lifespan of 5 years relative to male controls while women with PD had their lifespan reduced by 7 years compared to female controls (Figure 2). Women with PD (n = 77) had a greater reduction in lifespan relative to men with PD (n = 134) (P < 0.001). There was no difference in survival between men and women with PD in our sample (Figure 2). When the probabilities of each patient dying were calculated as described by Diamond and Markham [4] using annual or decennial U.S. Life Tables, the overall observed to expected mortality ratio for the 211 PD patients was 2.66. Mortality ratios were 2.28 for PD men and 3.76 for PD women relative to age-, gender-, and race-matched controls from the U.S. population.


Mortality in levodopa-treated Parkinson's disease.

Morgan JC, Currie LJ, Harrison MB, Bennett JP, Trugman JM, Wooten GF - Parkinsons Dis (2014)

Survival analysis of PD men and PD women versus control men and control women from the U.S. population. PD men and PD women have no difference in survival, while both PD men and PD women have reduced survival relative to control men and control women, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3927757&req=5

fig2: Survival analysis of PD men and PD women versus control men and control women from the U.S. population. PD men and PD women have no difference in survival, while both PD men and PD women have reduced survival relative to control men and control women, respectively.
Mentions: A Kaplan-Meier survival analysis illustrated in Figure 1 reveals that survival is reduced on average by 7 years in the entire sample of PD patients compared to an age-, gender-, and race-matched control group from the U.S. population. Men with PD had a mean reduction in lifespan of 5 years relative to male controls while women with PD had their lifespan reduced by 7 years compared to female controls (Figure 2). Women with PD (n = 77) had a greater reduction in lifespan relative to men with PD (n = 134) (P < 0.001). There was no difference in survival between men and women with PD in our sample (Figure 2). When the probabilities of each patient dying were calculated as described by Diamond and Markham [4] using annual or decennial U.S. Life Tables, the overall observed to expected mortality ratio for the 211 PD patients was 2.66. Mortality ratios were 2.28 for PD men and 3.76 for PD women relative to age-, gender-, and race-matched controls from the U.S. population.

Bottom Line: Our findings confirm that PD is associated with increased mortality in both men and women.Unlike the majority of other mortality studies, we found that women have a greater reduction in lifespan compared to men.We also found that patients with early onset PD (onset at the age of 50 or before) have reduced survival relative to PD patients with later ages of onset.

View Article: PubMed Central - PubMed

Affiliation: Movement Disorders Program, Department of Neurology, Medical College of Georgia, Georgia Regents University, 1429 Harper Street HF-1154, Augusta, GA 30912, USA.

ABSTRACT
Parkinson's disease (PD) is associated with increased mortality despite many advances in treatment. Following the introduction of levodopa in the late 1960's, many studies reported improved or normalized mortality rates in PD. Despite the remarkable symptomatic benefits provided by levodopa, multiple recent studies have demonstrated that PD patients continue to die at a rate in excess of their peers. We undertook this retrospective study of 211 deceased PD patients to determine the factors associated with mortality in levodopa-treated PD. Our findings confirm that PD is associated with increased mortality in both men and women. Unlike the majority of other mortality studies, we found that women have a greater reduction in lifespan compared to men. We also found that patients with early onset PD (onset at the age of 50 or before) have reduced survival relative to PD patients with later ages of onset. A final important finding is that survival is equal in PD patients treated with levodopa early (within 2 years or less of PD onset) versus later.

No MeSH data available.


Related in: MedlinePlus